PAHC vs the Top Picks average
| Pillar | PAHC | Book avg | Diff |
|---|---|---|---|
| Quality | 61 | 83 | -22 |
| Growth | 81 | 89 | -8 |
| Value | 72 | 76 | -4 |
Average of today's Top 30 (mean score 82.6); size and sector limits also decide the book.
One point per daily run; read From → To for the actual range.
PAHC at a glance
Same audited fundamentals as the score, unless a card says otherwise.
Analyst estimate revisions
| 30-day change | -0.2% |
|---|---|
| 90-day change | -0.2% |
| Forward EPS estimate | $3.84 |
Over the last 90 days, what analysts expect PAHC to earn is essentially unchanged. The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
A fiscal-year roll fell inside this window: the forward horizon moved on to the next financial year, which shifts the earnings figure without any analyst changing their view. That step is excluded, so the number above covers the rest of the window rather than all of it.
Estimates move both ways and are not part of the Bull Rankings score. Biggest movers →
Math only: excludes commissions, slippage and gap risk. Inputs stay in your browser.
Phibro Animal Health Corporation (PAHC): score, valuation & FAQ
Phibro Animal Health Corporation (PAHC) is a Drug Manufacturers - Specialty & Generic company that scores 70.7 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are P/E (A-) and Rev (B+), while FCF (C-) and D/E (D) rate weaker. On valuation, PAHC sits about 773% above our discounted-cash-flow fair value — the current price implies free cash flow growing over 60% next year, slowing to 4% a year by year ten.
Is PAHC a good stock to buy?
Bull Rankings scores PAHC 70.7 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by P/E (A-) and Rev (B+). A score is a quantitative screen of Phibro Animal Health Corporation's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does PAHC score 70.7 on Bull Rankings?
The score leans on growth at 80.6 out of 100, with quality the weakest pillar at 61.2 — the three combine geometrically, so a weak one cannot be papered over by a strong one. PAHC earns its highest marks on P/E (A-) and Rev (B+), and is held back by FCF (C-) and D/E (D). Each signal is graded against sector-aware thresholds rather than one absolute bar, so PAHC is measured against Drug Manufacturers - Specialty & Generic peers, not against the market as a whole.
Is PAHC overvalued or undervalued?
Based on $38.30, PAHC sits about 773% above our discounted-cash-flow fair value — the current price implies free cash flow growing over 60% next year, slowing to 4% a year by year ten. It trades at a 15.8x P/E (graded A-). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in PAHC?
D/E 2.06 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Down 36% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
New to these metrics? See the guides and the methodology.